Clinical characteristics of pyrazinamide-associated hepatotoxicity in patients at a hospital in Lima, Peru

Authors

  • Teodoro Oscanoa Centro de Investigación de Seguridad de Medicamentos, Facultad de Medicina Humana, Universidad de San Martín de Porres, Lima, Perú. Facultad de Medicina de la Universidad Nacional Mayor de San Marcos, Lima, Perú. Médico internista doctor en Medicina http://orcid.org/0000-0001-9379-4767
  • Saul Moscol Servicio de Neumología, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Perú. Médico Neumólogo http://orcid.org/0000-0002-6096-5571
  • José Amado Facultad de Medicina de la Universidad Nacional Mayor de San Marcos, Lima, Perú. doctor en Medicina http://orcid.org/0000-0002-3286-4650

DOI:

https://doi.org/10.17843/rpmesp.2020.373.4684

Keywords:

Tuberculosis, Drug Induced Liver Injury, Antituberculosis Drugs, Pyrazinamide, Adverse Drug Reaction, Length of Stay

Abstract

In order to determine the characteristics of drug-induced liver injury (DILI), adult patients diagnosed with tuberculosis and with an anti-tuberculosis treatment scheme including pyrazinamide were studied. The re-exposure process was used for the cause-effect analysis of the DILI. A total of 10 patients were found with pyrazinamide-associated DILI; the median age and hospital stay were 40.5 years (from 22 to 76 years) and 41 days (from 11 to 130 days), respectively. The median time in which the events appeared was 14 days (from 3 to 46 days); jaundice was observed in 4 patients and radiological patterns such as hepatocellular, mixed and cholestatic were found in 5, 3 and 2 patients, respectively. Mild presentation of DILI was observed in 6 cases (60%) and moderate in 3 (30%). In conclusion, pyrazinamide-associated DILI required prolonged hospital stay, presented jaundice in little more than a third of the cases, and radiologically, the hepatocellular pattern predominated.

Downloads

Download data is not yet available.

Author Biographies

  • Teodoro Oscanoa, Centro de Investigación de Seguridad de Medicamentos, Facultad de Medicina Humana, Universidad de San Martín de Porres, Lima, Perú. Facultad de Medicina de la Universidad Nacional Mayor de San Marcos, Lima, Perú. Médico internista doctor en Medicina

    Director del Centro de Investigación de Seguridad del Medicamento, Facultad de Medicina, Universidad de San Martin de Porres. Lima, Perú.

    Profesor Principal de la Facultad de Medicina de la Universidad Nacional Mayor de San Marcos.

  • Saul Moscol, Servicio de Neumología, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Perú. Médico Neumólogo
    Medico asistente del Servicio de Neumologia, Hospital Almenara, Lima Perú.
  • José Amado, Facultad de Medicina de la Universidad Nacional Mayor de San Marcos, Lima, Perú. doctor en Medicina
    Profesor Principal de la Facultad de Medicina de la Universidad Nacional Mayor de San Marcos.

Published

2020-09-02

Issue

Section

Brief Report

How to Cite

1.
Oscanoa T, Moscol S, Amado J. Clinical characteristics of pyrazinamide-associated hepatotoxicity in patients at a hospital in Lima, Peru. Rev Peru Med Exp Salud Publica [Internet]. 2020 Sep. 2 [cited 2024 Mar. 4];37(3):516-20. Available from: https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/4684

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>